Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 109

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 109
---
 from this offering. We believe that after the completion of this offering our cash and cash equivalents,
including the proceeds from this offering, will enable us to fund our operations through March 31, 2027.

Through June 30, 2025,
we have financed our operations primarily through private placements, convertible loans and short-term loans. Total invested capital
as of each June 30, 2025 and December 31, 2024 was $36.2 million, which included Ordinary Shares, Preferred Shares and warrants
to purchase Preferred Shares.

The following table summarizes
our statement of cash flows for the years ended December 31, 2024 and 2023 and the six months ended June 30, 2025 and 2024:

| (U.S.                                                 
 dollars in thousands except share and per share data) |     | 2024 |             For 
 the Years Ended 
    December 31, |   |     | 2023 |        |   |     | 2025 |                  For 
 the Six Months Ended 
             June 30, |   |     | 2024 |      |   |
|:------------------------------------------------------|:----|:-----|----------------:|:--|:----|:-----|-------:|:--|:----|:-----|---------------------:|:--|:----|:-----|-----:|:--|
| Net cash provided by (used                            
 in) operating activities                              |     | $    |            (641 | ) |     | $    | (1,220 | ) |     |      |                 (340 | ) |     |      |    6 |   |
| Net cash used in investing activities                 |     |      |               - |   |     |      |      - |   |     |      |                    - |   |     |      |    - |   |
| Net cash provided                                     
 by (used in) financing activities                     |     |      |             525 |   |     |      |    325 |   |     |      |                  300 |   |     |      | (175 | ) |
| (Decrease) Increase                                   
 in cash and cash equivalents                          |     | $    |            (116 | ) |     | $    |   (895 | ) |     |      |                  (40 | ) |     |      | (169 | ) |

<div align='center'>68</div>

Net cash